leadf
logo-loader
viewPharmaxis Ltd
(
ASX:PXS
)

Pharmaxis encouraged by first results in bone marrow cancer trial

Pharmaxis Ltd’s (ASX:PXS) Gary Phillips says first results from a three-stage phase 1c clinical trial (MF-101) studying a potential treatment for bone marrow cancer myelofibrosis, have demonstrated strong inhibition of target enzymes LOX and LOXL2 in patients. The study aims to demonstrate that PXS-5505 is safe and effective as a monotherapy in myelofibrosis patients who are intolerant, unresponsive or ineligible for treatment with approved JAK inhibitor drugs.

Quick facts: Pharmaxis Ltd

Follow
ASX:PXS

Price: 0.1275 AUD

Market Cap: $57.85 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Pharmaxis hails positive results in Phase 1 scarring trial

Pharmaxis Ltd (ASX:PXS)'s Gary Phillips speaks to Proactive following the news its novel topical drug treatment for scarring has delivered positive phase 1 clinical trial results and will now advance to the next stage of development in patients. He says in a study of healthy volunteers PXS‐6302...

3 weeks, 4 days ago

2 min read